
    
      This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242
      compared to placebo over 14 days twice a day dosing in multiple ascending doses in subjects
      with stable schizophrenia.

      This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to
      Biogen.
    
  